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A new time- and energy-saving method for the determination of asymmetric
dimethylarginine in human serum is presented. Here, a newly developed eluent
was used in the sample cleanup of the solid-phase extraction whose composition
makes an evaporation step redundant. After derivatization, asymmetric dimethy-
larginine was quantified by high-performance liquid chromatography with fluo-
rescent detection. The conditions of the solid-phase extraction lead to a relative
recovery of asymmetric dimethylarginine of 101%. A concentration of 25 ng/mL
was found as the limit of quantification and the batch was highly linear from
25 to 800 ng/mL with the correlation coefficient R2 = 0,9999. Intra-assay coeffi-
cients of variation <2.1% and inter-assay coefficients of variation <3.1% indicate
a high precision. Since no evaporation is necessary compared to previously pub-
lished methods, this newly presented method does not only save time, but also is
a cost- and energy-saving alternative for the routine quantification of asymmetric
dimethylarginine in serum.
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1 INTRODUCTION
Asymmetric dimethylarginine (ADMA) is an endogenous
inhibitor of nitric oxide synthase (NOS) [1] and therefore,
plays an important role inter alia in endothelial function.
Article Related Abbreviations: ADMA, asymmetric
dimethylarginine; CV, coefficient of variation; L-NMMA,
monomethylarginine; MEA, monoethylarginine; NOS, nitric oxide
synthase; SDMA, symmetric dimethylarginine; SPE, solid-phase
extraction
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In addition to ADMA, there are the methylated arginine
derivatives symmetric dimethylarginine (SDMA) and
monomethylarginine (L-NMMA). However, ADMA is a
much more potent inhibitor of NOS than SDMA [2] and
the concentration of ADMA in the circulation is signif-
icantly higher than that of L-NMMA [2,3]. So, ADMA
has the greatest physiological and pathophysiological
importance of these derivatives.
Various methods for measuring the serum concen-
tration of ADMA are described in the literature. The
most commonly used method for this purpose is the
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determination by HPLC with fluorimetric detection after
solid-phase extraction (SPE) [4,5]. Furthermore, it is also
possible to quantify ADMA by LC–MS [6], GC–MS [7], or
ELISA [8]. However, an HPLC method with fluorimetric
detection is more cost-saving than a method using mass
spectrometry [5] and more precise than an ELISA assay
[9]. In previously described HPLC methods, the sample
preparation was carried out by SPE and subsequent evapo-
ration of the SPE eluent [1,10–14]. The eluents used for the
SPE process usually contain ammonia and methanol [4].
A disadvantage of these methods is that the evaporation
step takes a lot of time and thus extends the total analysis
time. Therefore, these methods are only of limited use for
routine determinations of ADMA concentrations and for
large-scale studies.
For this reason, a time-saving and reliable assay to deter-
mine concentrations of ADMAby using a newly developed
SPE eluent, which makes the evaporation step redundant,
is presented.
2 MATERIALS ANDMETHODS
2.1 Materials and equipment
NG,NG-Dimethylarginine dihydrochloride (ADMA),
phthaldialdehyde, and 3-mercaptopropionic acid were
obtained from Sigma–Aldrich (Seelze, Germany). NG-
Monoethyl-l-arginine TFA (MEA, internal standard) was
purchased from Santa Cruz Biotechnology (Heidelberg,
Germany). Methanol, acetonitrile, potassium chloride,
potassium borate, and potassium hydroxide were obtained
from Merck (Darmstadt, Germany). Hydrochloric acid
0.1 M was purchased from VWR Chemicals (Darmstadt,
Germany) and potassium dihydrogen phosphate from
Carl Roth (Karlsruhe, Germany).
Water was deionized and filtered using the water
purification system Arium R© Basic from Sartorius
(Goettingen, Germany). HPLC was carried out by a
Shimadzu (Duisburg, Germany) Prominence R© system
with an RF-10AXL R© fluorescence detector. The soft-
ware LabSolutions R© from Shimadzu was used for data
acquisition and evaluation.
2.2 Preparation of standards
Stock solutions of ADMA (100 μg/mL = 0.494 mM)
and monoethylarginine (MEA, 1 mM) were prepared in
10 mM hydrochloric acid and stored at -80◦C. Calibration
standards of ADMA with 50, 100, and 200 ng/mL were
prepared by diluting the stock solution with water. A
working solution of the internal standard MEA (5 μM)
was prepared by diluting the stock with water. The use
of the non-endogenous internal standard MEA was first
described by Blackwell et al. [10].
2.3 Sample preparation
The SPE procedure and derivatization were executed
according to Teerlink et al. [1] with modifications. For
extraction the cartridges Oasis R© MCX 1cc 10 mg 30 μm
from Waters (Eschborn, Germany) were used. The novel
SPE eluent was prepared with 0.4 g potassium chloride,
5.96 mL water, 0.04 mL 5M potassium hydroxide solution,
and 4 mL methanol.
First, the cartridgeswerewashedwith 0.5mLSPE eluent
and equilibrated with 0.5 mL water. Serum (0.1 mL) or cal-
ibration standard was mixed with 0.05 mL MEA working
solution and 0.35 mL water until loading on the cartridge.
After two washing steps with 0.5 mL 0.1 M hydrochloric
acid and 0.5 mL methanol, the analytes were eluted in
HPLC vials with 0.3 mL SPE eluent [1].
A stock solution of the derivatization reagent was pre-
pared with 10 mg O-phthaldialdehyde (OPA), 0.2 mL
methanol, 1.8 mL potassium borate buffer 0.2 M pH 9.5,
and 10 μL 3-mercaptopropionic acid. A working solution
was prepared by diluting the stock solution 1:5 with the
borate buffer.
Working solution (0.3 mL) was added to the HPLC vials
containing the analyte and incubated for 3 min at room
temperature [1]. Then, the vials were transferred to the
autosampler.
2.4 Chromatography
HPLC was carried out by a Shimadzu (Duisburg, Ger-
many) Prominence R© system consisting of the degasser
DGU-20A 3R R©, the two pumps LC-20AT R©, the autosam-
pler SIL-20ACHT R©, the columnovenCTO-10ASVP R©, the
system controller CBM-20A R© and the fluorescence detec-
tor RF-10AXL R©. As analytical column, a Kinetex R© EVO
C18 2.6 μm 150 × 4.6 100A protected by a SecurityGuard
Ultra R© cartridge for EVO-C18 (Phenomenex, Aschaffen-
burg, Germany) was used.
Mobile phase was a potassium phosphate buffer 25 mM
pH 6.5 containing 9.7% acetonitrile. Five microliter was
injected into the system and separated at a flow rate
of 1 mL/min and a column temperature of 40◦C. Run-
time was 13 min and fluorescence was measured at
excitation of 340 nm and emission of 455 nm. ADMA
was quantified on the basis of the ratio of peak areas.
An isocratic washing step was performed by increas-
ing the proportion of acetonitrile to 35% for 10 min.
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F IGURE 1 Representative chromatogram of a serum sample analyzed with the described method for ADMA determination. The concen-
tration of ADMA in this serum sample is 92.9 ng/mL. Analytical column: Kinetex R© EVO C18 2.6 μm 150 × 4.6 100 A; mobile phase: potassium
phosphate buffer 25 mM pH6.5 containing 9.7% acetonitrile; flow rate: 1 mL/min; runtime: 13 min; column temperature: 40◦C; fluorimetric
detection at excitation of 340 nm and emission of 455 nm
Afterward, the column was equilibrated for 6 min with
9.7% acetonitrile.
2.5 Method validation
To analyze the LOQ, the baseline noise was determined
and compared to the height of the ADMA peak. The LOQ
was defined as the concentration point where the signal-
to-noise ratio was 10.
The LOD has not been determined for this method as all
human serum contains ADMA. Only the concentration of
ADMA can be altered by pathological conditions. To date,
no diseases are known to cause ADMA to be undetectable
in serum.
For analysis of assay linearity, a calibration curve was
constructed using six calibration points (25, 50, 100, 200,
400, 800 ng/mL), thereby receiving equation and correla-
tion coefficient of the calibration curve.
For ADMA, no certified reference standards were avail-
able to check accuracy. So, for each calibration point, the
ADMA concentrationwas calculated from the signal using
the equation of the linear calibration curve. Accuracy was
analyzed by comparison of the calculated ADMA concen-
tration with the real ADMA concentration and deviation
was expressed as bias.
Precision of the method was tested using two differ-
ent serum samples that contained a high or a low ADMA
concentration. Both serum samples were measured three
times a day on 6 days and the intra-assay and the inter-
assay coefficients of variation (CVs) were calculated.
The effect of the matrix on linearity was analyzed
according to Teerlink et al. [1]. To various volumes (25, 50,
100, 150, 200, 250 μL) of a serum pool, 50 μL MEA work-
ing solution was added and adjusted to a total volume of
500 μL with water. It was investigated if plots of the calcu-




The chosen conditions resulted in 93.4% (n= 6) SPE recov-
ery of ADMA and 92.8% (n = 6) SPE recovery of MEA.
Thus, the relative recovery of ADMA was 101%. Evapora-
tion of the eluent after SPE was not necessary, since it con-
tained no ammonia that could reactwith the derivatization
reagent.
3.2 Chromatography
In Figure 1, a typical chromatogram of a serum sample
is shown. The chromatographic conditions after SPE
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F IGURE 2 Representative chromatogram of an aqueous calibration solution that has been prepared in the same way as a serum sample
with the described method. This solution contains ADMA at a concentration of 100 ng/mL. Analytical column: Kinetex R© EVO C18 2.6 μm
150 × 4.6 100A; mobile phase: potassium phosphate buffer 25 mM pH6.5 containing 9.7% acetonitrile; flow rate: 1 mL/min; runtime: 13 min;
column temperature: 40◦C; fluorimetric detection at excitation of 340 nm and emission of 455 nm
procedure and derivatization led to baseline separation of
the ADMA peak and the MEA peak. The separation per-
formance, expressed as calculated number of theoretical
plates, was 10 425 and thus correspond to the state of the
art. In the serum, the chromatogram of which is shown
in Figure 1, an ADMA concentration of 92.9 ng/mL was
measured. For comparison, a chromatogram of an aque-
ous calibration solution containing 100 ng/mL ADMA is
shown in Figure 2.
3.3 Method validation
An ADMA concentration of 25 ng/mL was found as the
LOQ. The calibration curve of the ratios of peak area of
ADMA and MEA against ADMA concentration shown in
Figure 3 was highly linear with R2 = 0.9999 in the range
from 25 to 800 ng/mL. Outliers were not obtained. The
coefficients of variation (CVs) of the calibration concentra-
tions were low with a maximum of 2.8%. This high linear-
ity was to be expected, since fluorescence detectors usually
show linear detector response over several orders of mag-
nitude [4].
Accuracy and precision data of the method are shown
in Table 1. The deviation between calculated ADMA con-
centration and real ADMA concentration was 12% at the
LOQ and 5.6% at a concentration of 50 ng/mL. For all other
concentrations of the calibration curve (100–800 ng/mL),
the bias was less than 3.0% indicating the accuracy of the
method.
Intra-assay CVs of the concentration were <2.1% and
inter-assay CVs were <3.1%. Thus, the developed method
allows a precise measurement of the ADMA concentra-
tion.
Plots of calculated ADMA concentration versus volume
of serum pool were linear with R2 = 0.9978. So, there are
no significant matrix effects.
4 DISCUSSION
The applied cartridgeswere based onOasis R©MCX that is a
reversed-phase, strong cation-exchange polymer contain-
ing sulfonic acid groups. Due to their high acidity, the sul-
fonic acid groups deprotonate and are negatively charged
during the SPE process. Since deprotonated sulfonic acid
groups can interact well with positively charged proto-
nated bases such as guanidine groups, this polymer is suit-
able to separate the basic arginine derivatives from other
amino acids.
In the standard protocol of Oasis R© MCX an eluent
containing ammonia is recommended. However, the
use of ammonia requires a time-consuming evaporation
step after the SPE as it can react with the derivatization
reagent. In previously published methods, the eluent
often contains about 40% water in addition to methanol
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F IGURE 3 Linearity of the method: calibration curve (ratio of peak area of ADMA and MEA versus ADMA concentration) with ADMA
concentrations ranging from 25 to 800 ng/mL. The standard deviations are shown as bars at the respective concentrations. The equation of
the linear regression line was y = 0.1750x – 0.8012 whereby x = c(ADMA) and y = 100 × peak area(ADMA)/peak area(MEA). c(ADMA),
concentration of ADMA
TABLE 1 Accuracy and Precision data of the described
method. These data show the reliability of the method
Accuracy c(ADMA) [ng/ml] Bias [%]









CV intra-assay (n= 3 × 6 a ) Low ADMA 2.1
High ADMA 1.9
CV inter-assay (n= 6 × 3 a ) Low ADMA 3.1
High ADMA 2.8
aFor the calculation of CVs, serum samples were measured 3 times a day on
6 days.Abbreviations: c(ADMA), concentration of ADMA; CV, coefficient of
variation.
and ammonia [1,10,13]. Due to this high proportion of
water, evaporation of the eluent is a time-consuming
step, leading to longer sample preparation times. Thus, a
newly developed eluent without ammonia was used for
the presented SPE procedure. To remove the analyte from
the strong cation exchange polymer, the eluent should be
basic and have a high cation concentration. These condi-
tions were fulfilled by adding potassium hydroxide and
potassium chloride to methanol and water. By applying
the newly developed eluent, the evaporation after SPE was
not necessary resulting in a significantly shorter sample
preparation time. Consequently, energy can be saved,
and costs are reduced, since time-consuming evaporation
would also be associated with power consumption. The
recoveries of ADMA (93.4%) and MEA (92.8%) after SPE
under these conditions are adequate.
In comparison to the method of Teerlink et al. [1], fur-
ther modifications were made: instead of L-NMMA, the
non-endogenous substance MEA was used as the internal
standard. As a result, the developed method is less suscep-
tible to errors than methods using endogenous substances
such as L-NMMAor homoarginine. These arginine deriva-
tives may be elevated in pathological conditions, such as
renal failure, where ADMAmay also be elevated [10]. The
relative SPE recovery of ADMA of 101% demonstrates the
utility of MEA as the internal standard.
Teerlink et al. used Oasis MCX 30 mg for the SPE
method [1] while Oasis MCX 10 mg is used for the present
method. Therefore, only 0.1 mL serum instead of 0.2 mL is
needed for the determination of ADMA.
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Another advantage of this method is the use of a
semiporous column with a small particle size of 2.6 μm
(Kinetex R© EVO C18 2.6 μm) instead of a 5 μm column
[1] for chromatography. The high resolution of that col-
umn allows application of a comparatively high propor-
tion of acetonitrile in the eluent, leading to a shorter run
time.
In Teerlink’s method, the chromatographic separation
was performed at a column temperature of 30◦C [1]. The
increase of column oven temperature during the develop-
ment of the present method up to 40◦C has shortened the
run time without loss of resolution.
Furthermore, the number of calibration points has been
increased from one [1] to three, resulting in a more accu-
rate evaluation.
The determined LOQ of 25 ng/mL is sufficient for the
measurement of ADMA in plasma [4]. Since the concen-
tration of ADMA in plasma does not differ significantly
from that in serum [1], this value is also adequate for the
quantification of ADMA in serum. The concentration of
ADMA in serum is expected to be within the established
linear range of 25–800 ng/mL [4,15].
The calculated inter-assay and intra-assay CVs of this
method are very low with values <3.1 and <2.1%, respec-
tively. The resulting high precision enables a reliable deter-
mination of the serum concentration of ADMA [10].
5 CONCLUDING REMARKS
In summary, a reliablemethod for quantification ofADMA
in serum was developed by introducing a new eluent for
the SPE procedure. The main advantages of this method
are savings in time, cost, and energy, as evaporation of the
new eluent is redundant. Thus, this method is suitable for
routine analysis of serum concentrations of ADMA and for
large scale studies. Nevertheless, further improvements of
the method are possible, such as automatic derivatization
or automation of the SPE process. Since no evaporation is
required, the method should be well suited for automati-
zation.
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